- Home
- PEBK vs OABI Comparison
PEBK vs OABI Comparison
Compare PEBK & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PEBK | OABI |
|---|---|---|
| Founded | 1912 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.9M | 237.4M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | PEBK | OABI |
|---|---|---|
| Price | $42.15 | $2.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 25.3K | ★ 712.9K |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 21.48 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | $53.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.81 | $1.22 |
| 52 Week High | $42.73 | $2.61 |
Technical Indicators
Market Signals| Indicator | PEBK | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 63.18 | 86.31 |
| Support Level | $38.84 | $1.43 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.07 | 0.16 |
| MACD | 0.20 | 0.11 |
| Stochastic Oscillator | 72.18 | 93.84 |
Price Performance
Historical ComparisonAbout PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.